BBK Worldwide, patient recruitment leader and clinical research and development consultancy, announces the opening of a West Coast office in Los Angeles. This expansion is a response to increasing demands from biotechnology/biopharmaceutical research sponsors for worldwide coverage to successfully meet recruitment deadlines. Building on the 2009 office opening of BBK Worldwide – Osaka in Japan, and adding to BBK’s existing global alliance network and Boston, London, and Prague locations, the Los Angeles office creates an opportunity for BBK to better serve clients in the Pacific time zone.
According to BBK Founding Principal Joan F. Bachenheimer, “Our West Coast clients operate in a hotbed of biopharmaceutical innovation. BBK’s on-site consultation better ensures their trials are primed for success with early recruitment strategies, technology, training, and tactical implementation support.”
On assignment from BBK’s global mobilization team, project and marketing experts will staff and augment the West Coast workforce, as needed, to respond directly to client and campaign needs. “Putting ‘feet on the street’ via a West Coast office means that we can better partner with clinical team leads as well as provide immediate, and if necessary, on-site enrollment coaching and training to study coordinators and site staff,” Bachenheimer added.
BBK Director of Strategic Development Andrew N. Sacher, Esq. commented, “We are finding with our presence in Osaka that real-time BBK availability in a region focused on biopharmaceutical innovation empowers clients to invest in the most advanced patient recruitment techniques. By opening the West Coast office, we anticipate spurring similar interest and commitment to enhancing clinical trial enrollment – particularly as the sheer number of biopharmaceutical studies being conducted continues to rise.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.